Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Principal Investigator

Dr Srilakshmi Sharma

Contact us

Email: ERGO@ouh.nhs.uk

IRAS number

1013638